enVVeno Medical reports Q3 EPS (45c) vs. (54c) last year

“Our team has continued to make significant progress on multiple fronts while keeping our cash burn in line with previous guidance. Notably, we reached full enrollment, ahead of schedule, in the VenoValve U.S. pivotal trial, further strengthened our balance sheet with the closing of a $28 million private placement on terms that are favorable to both the company and investors, and in light of our stronger cash position, announced our plans to expedite the development of enVVe, our transcatheter replacement venous valve,” commented Robert Berman, CEO of enVVeno Medical. “Although we expect our quarterly cash burn to begin to increase over time as we get closer to commercialization of the VenoValve, we now have the capital that we need to get us past several significant milestones, including what we expect will be regulatory approval of the VenoValve and the beginning the enVVe pivotal trial.”